PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Eli Lilly
Adaptive Trial Design and Combo Drugs Needed in Alzheimer’s
FDA’s head of neurology products told industry execs at the Prix Galien Forum that the agency is open to alternative clinical trial designs in Alzheimer’s disease, and would like to see more combination products in clinical testing.
Posted in Agency Insight, FDA, R&D, Regulatory Also tagged Alzheimer's disease, Clinical Trials Leave a comment
Diabetes Drug Launch 2012: Tip-tops and Promo-flops
With Halloween candy flooding the shelves in pharmacies across the nation, it’s only appropriate that we turn the conversation toward an ever-growing drug market and therapeutic area: diabetes.
Posted in Advertising, E-Media, FDA, Marketing, Meetings, Strategy Also tagged Amylin, Boehringer Ingelheim, Launch, Merck, Professional Marketing 1 Comment
New Non-Profit Alliance of Big Pharma Firms
By Amy Ritter.
Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
Posted in Biotech, Deals, Guest Blog Also tagged Abbott, AstraZeneca, Big Pharma, biopharm, BMS, Genentech, GlaxoSmithKline, Pfizer, Roche, Sanofi Leave a comment
Fixing Innovation: Lilly's CEO Says Why, and How
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing Also tagged CEO, CEOs, drug safety, Financial Times, Global, healthcare reform, innovation, IP, IPAB, Lilly, PhRMA, policy, R&D 1 Comment
Pipeline Report Preview